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Abstract 
 
Antibodies are extensively used in research for diagnostic and therapeutic purposes because of 
their unrivaled specificity and biomarker binding strengths.1 Currently, monoclonal antibodies are 
most commonly used because of their production consistency and purity.1 However, there are 
significant ethical and economic challenges associated with producing monoclonal antibodies.1 
Synthetic antibodies provide a promising alternative to monoclonal antibodies in both clinical and 
research applications.2  
 
Our proposed synthetic antibody system incorporates 3,4-dihydroxy-l-phenylalanine (L-DOPA), 
an unnatural amino acid used to increase binding affinity, into a peptide sequence specific for the 
prostate specific antigen (PSA), a biomarker for prostate cancer. This addition is predicted to give 
the synthetic antibody binding affinity and PSA specificity comparable to existing monoclonal 
antibodies while avoiding their drawbacks.3 If successful, our system would replace monoclonal 
antibodies for PSA detection as well as be a promising model for developing countless other 
synthetic antibodies. 
  
iv 
 
Acknowledgments 
 
Dr. Zhiwen (Jonathan) Zhang 
 
Santa Clara University, School of Engineering 
 
Santa Clara University, Department of Bioengineering 
 
Santa Clara University, Undergraduate Programs Senior Design Project Fund 
 
 
  
v 
 
Table of Contents 
 
Abstract ......................................................................................................................................... iii 
Acknowledgments ........................................................................................................................ iv 
List of Figures .............................................................................................................................. vii 
Abbreviations ............................................................................................................................. viii 
Introduction ................................................................................................................................... 1 
Background, Significance, & Motivation ............................................................................................. 1 
Literature Review ................................................................................................................................... 3 
Critiques of Current Literatures and Technologies ............................................................................ 6 
Project Objectives ................................................................................................................................... 7 
Overall Design ......................................................................................................................................... 7 
Milestones & Expected Results............................................................................................................ 10 
Team Management ............................................................................................................................... 11 
Chapter 1: Vector Design & Cloning ........................................................................................ 12 
Introduction .......................................................................................................................................... 12 
Back-up Plan ......................................................................................................................................... 12 
Design Logic and Reasoning ................................................................................................................ 12 
Materials and Methods ........................................................................................................................ 14 
Results .................................................................................................................................................... 15 
Discussion .............................................................................................................................................. 17 
Chapter 2: Protein Expression .................................................................................................. 18 
Introduction .......................................................................................................................................... 18 
Back-up Plan ......................................................................................................................................... 19 
Materials and Methods ........................................................................................................................ 19 
Results .................................................................................................................................................... 21 
Discussion .............................................................................................................................................. 21 
Chapter 3: Protein Purification ................................................................................................. 23 
Introduction .......................................................................................................................................... 23 
vi 
 
Back-up Plan ......................................................................................................................................... 23 
Materials and Methods ........................................................................................................................ 23 
Results .................................................................................................................................................... 24 
Discussion .............................................................................................................................................. 25 
Chapter 4: Conclusion ................................................................................................................ 26 
Testing & Analysis ................................................................................................................................ 26 
Summary and Future Applications ..................................................................................................... 27 
Chapter 5: Ethical Concerns...................................................................................................... 28 
Chapter 6: Engineering Standards and Realistic Constraints ............................................... 29 
Economic ............................................................................................................................................... 29 
Ethical .................................................................................................................................................... 29 
Social ...................................................................................................................................................... 30 
Manufacturability ................................................................................................................................. 30 
Health & Safety ..................................................................................................................................... 31 
References .................................................................................................................................... 32 
Appendix ...................................................................................................................................... 34 
Appendix A: pAC DHPheRS-6TRN plasmid map ............................................................................ 34 
Appendix B: Experimental Vector ...................................................................................................... 35 
Appendix C. Experimental Vector: pET28-P1+GFP+His Sequencing Information ...................... 36 
Appendix D. Control Vector: pET28-P1+GFP+His Sequencing Information ................................ 41 
Appendix E. Cloning Reactions ........................................................................................................... 48 
Appendix F. Project Expenses ............................................................................................................. 50 
Appendix G. Project Timeline ............................................................................................................. 51 
 
 
 
  
vii 
 
List of Figures   
Figure 1: Specific Antibody-Antigen Binding ............................................................................ 1 
Figure 2. Increased levels of PSA indicate prostate cancer ...................................................... 2 
Figure 3. Synthetic Antibody Detection and Binding of PSA ................................................... 8 
Figure 4. Experimental and control nucleotide design sequence alignment ......................... 13 
Figure 5. Step-by-step of double digestion of vector to insert peptide ................................... 13 
Figure 6. 1% agarose gel for pET28b-GFP .............................................................................. 15 
Figure 7. Sequence Alignment of Experimental (Query) and Control (Sbjct) Vectors........ 16 
Figure 8. Chromatograms. ......................................................................................................... 17 
Figure 9. Sequential co-transformation of pET28b+P1+GFP and pAC-DHPheRS-6TRN . 18 
Figure 10. Transformed E. coli + pAC-DHPheRS-6TRN. ...................................................... 21 
Figure 11. Experimental (A), control (B), and no GFP (C) cultures ...................................... 21 
Figure 12. SDS-PAGE of purification ....................................................................................... 24 
        
 
 
viii 
 
Abbreviations            
 
CIP: Calf Intestinal Phosphatase 
E. coli: Escherichia coli 
ELISA: Enzyme-linked Immunosorbent Assays 
FPLC: Fast Protein Liquid Chromatography 
GFP: Green Fluorescent Protein 
6-His: Poly-histidine Amino Acid Motif 
IPTG: Isopropyl β-D-1-thiogalactopyranoside 
ITC: Isothermal Titration Calorimetry  
kDA: kilo Dalton 
Kan: Kanamycin 
Kd: Dissociation Equilibrium Constant 
LB: Lysogeny Broth 
L-DOPA: l-3, 4-dihydroxyphenylalanine 
MW: Molecular Weight 
NEB: New England Biolabs 
OD600: Optical Density at 600nm 
PBS: Phosphate Buffered Saline 
PMSF:  Phenylmethane Sulfonyl Fluoride 
PSA: Prostate Specific Antigen 
P1: Peptide One 
Rpm: Revolutions Per Minute 
SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
TAG: Amber Stop codon 
Tet: Tetracycline 
tRNA: Transfer Ribonucleic Acid 
UV: Ultraviolet 
  
1 
 
Introduction             
 
 
Background, Significance, & Motivation 
Antibodies are naturally produced by the immune system to fight off foreign invaders.1 Because 
they are specific to a single antigen on a pathogen or infected cell and bind strongly to this 
antigen, immune cells are able to locate and destroy these target cells effectively (See Figure 1).1 
In order to take advantage of the naturally high strength and specificity of antibody-antigen 
interactions, scientific researchers have commercialized antibodies for diagnostic and therapeutic 
purposes.1 Diagnostic applications include Western blots and ELISA, which detect the presence 
of specific proteins, antibodies, or antigens in a given sample.1 Transducer-based assays are other 
diagnostic tools that use antibodies for a wide range of applications, including cancer and 
diabetes screening.4 Therapeutic antibodies are used to treat autoimmune disorders, 
cardiovascular diseases, and types of cancer.5 
 
 
Figure 1: Specific Antibody-Antigen Binding 
 
One application of these commercial antibodies is prostate cancer detection. Prostate cancer is 
the second most common cancer among men. One in seven men will be diagnosed with prostate 
cancer in his lifetime.6 Like most cancer, it is crucial to detect the cancer early, before it 
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metastasizes.6 If detected early enough, 96% of diagnosed men will live another 15 years. There 
are two main methods of detecting prostate cancer.6 One indication is an enlarged or abnormal 
prostate discovered during a digital rectal exam.6 Another is the level of PSA in the blood.6 As 
shown in Figure 2, a healthy prostate secretes a small amount of PSA.6 However, a higher level 
of PSA in the blood is seen in those with prostate cancer.6 During routine blood work, the 
amount of PSA can be detected using a monoclonal antibody.7 
 
Figure 2. Increased levels of PSA indicate prostate cancer. 
 
Monoclonal antibodies are the gold standard in research and medical applications because of 
their inherent consistency and purity.1 However, disadvantages of using monoclonal antibodies 
include batch-to-batch variability, ethical concerns, and an expensive and lengthy production 
process.1 Synthetic antibodies provide a promising alternative to monoclonal antibodies because 
they overcome many of the significant drawbacks of monoclonal antibodies while maintaining 
comparable function.8  
 
This project focuses on the development of a synthetic antibody, produced in E. coli, using L-
DOPA, an unnatural amino acid, incorporation for detection of prostate cancer. The antibody is 
specific for PSA, which can indicate prostate cancer at elevated levels.7 This synthetic antibody 
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design offers comparable specificity and binding strength to the monoclonal antibody while also 
minimizing the drawbacks involved with production. If successful, this system would replace 
monoclonal antibodies for PSA detection, be a promising model for developing countless other 
synthetic antibodies, and contribute to the development of personalized medicine in the future. 
 
Literature Review         
Design 
The basis of this project is a paper by Umeda et al. which details the incorporation of an 
unnatural amino acid, L-DOPA, to a peptide (TOP1), GFP reporter protein, and 6-His 
purification tag.3 This system, with the exception of the peptide sequence specific for PSA, is the 
same as the proposed system of this project. The peptide of the synthetic antibody described in 
the paper is specific to the antigen Abelson tyrosine kinase (AbI).3 Similarly, Therriault and 
Evans designed a system with a similar design to that of Umeda et al. that targets PSA.14 
Although these systems differ from the synthetic antibody in structure and target, the methods 
and protocols for unnatural amino acid incorporation and protein expression used in these papers 
will be a model and starting point for procedures used throughout this project. 
 
Unnatural Amino Acids 
Unnatural amino acids are amino acids not used by ribosomes in cells to make proteins 
naturally.8 They can have unique chemistry compared to natural amino acids and have therefore 
been proposed as a solution to the inherently weak binding strength between small peptides and 
larger proteins when incorporated into the peptide.3 L-DOPA is the unnatural amino acid used by 
Umeda et al. to increase the binding strength of a small peptide to a larger protein.3 The 
unnatural amino acid performs a redox reaction with a nearby nucleophile in the presence of 
sodium periodate, creating a strong covalent bond.3 L-DOPA is particularly useful for unnatural 
amino acid incorporation into a recombinant protein because it is orthogonal to natural amino 
acids, which ensures correct translation of the peptide including incorporation of L-DOPA.3 L-
DOPA will therefore be used in this project to increase the binding strength of the synthetic 
antibody to PSA using a covalent bond. 
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Unnatural amino acids such as L-DOPA can be incorporated into the peptide by introducing into 
the cell a mutant tRNA and tRNA synthetase, which are designed to recognize the amber stop 
codon (TAG/UAG) on mRNA and incorporate the unnatural amino acid at that location on the 
growing peptide.8 The amber stop codon is used because of the three stop codons used naturally, 
it is the least frequently used in E. coli (7%) and is rarely is used on essential proteins.8 Using 
this stop codon minimizes the likelihood of unnatural amino acid incorporation disrupting 
normal cell function and killing the cell.8 The amber stop codon will therefore be used to 
incorporate L-DOPA into this synthetic antibody. The pAC-DHPheRS-6TRN plasmid used by 
Therriault and Evans contains the genetic code for the mutant tRNA and tRNA synthetase, and 
will be used in this project.14  
 
The use of unnatural amino acid incorporation in any protein, peptide, or small molecule system 
is a cutting edge technology.9 Researchers and pharmaceutical companies have began using this 
technology to engineer antibodies.9 As this process is developed, they experience many obstacles 
to synthetic antibody expression and manufacturing.9 These production challenges will be 
important considerations in this project as it attempts to develop an accessible and viable product 
for companies.9 The solutions other researchers discovered to overcome these challenges will be 
helpful for this project.9  
 
One issue faced by researchers incorporating unnatural amino acids at the carboxy terminus of a 
gene is truncation of the protein.10 It is very difficult to separate the truncated protein from the 
fully-translated protein, and a group of researchers overcame this issue by attaching an intein 
protein.10 The intein protein is attached with a tag after the unnatural amino acid amber stop 
codon and promotes full translation of the protein.10 This method achieves higher purity and 
function and avoids a commonly encountered problem when purifying unnatural amino acids.10 
This method would be considered for this project if truncated protein expression becomes an 
issue.  
 
Methods and Procedures 
One major benefit of this project is avoiding using animals to produce antibodies.8 Instead, E. 
coli will be used to produce comparable antibodies.8 E. coli are commonly used for protein 
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production because introducing exogenous recombinant DNA, such as the plasmid for the 
synthetic antibody, into them is an established process.18 In addition, by using E. coli, the 
synthetic antibody production is able to avoid the ethical concerns of using and killing animals.11 
The use of E. coli also limits economic cost, as scaling up production in E. coli is fast due to the 
short doubling time of the cells, allowing for high density cultures in bioreactors with simple 
growing conditions, rather than requiring large animal facilities.18 These characteristics of E. coli 
as a production platform therefore make it ideal for use in this project. 
 
However, since there are big differences between mammalian and E. coli protein production, it is 
important to understand the drawbacks to using E. coli.8 These include susceptibility to genetic 
mutations as well as the lack of ability to perform post-translational modifications.8 Since the 
synthetic antibody used in this project will only be 45 nucleotides, sequencing will be used to 
verify the DNA sequence is correct. The synthetic antibody also does not require any post-
translational modifications because of its length, making E. coli a simple and effective 
expression platform. 
 
There are three published methods of protein expression with L-DOPA incorporation into 
peptides with similar designs to this project’s synthetic antibody.3,16,17 They vary by inducer, 
incorporation time, and induction and growth times. To optimize expression and yield of the 
synthetic antibody, this project will perform separate but simultaneous experiments using each of 
these three methods to identify and develop the most effective expression protocol. 
 
 
Prostate Cancer Detection 
After successfully producing the synthetic antibody, one important aspect of this project will be 
assessing whether it is truly comparable to monoclonal antibodies for both diagnostic and 
therapeutic applications. Researchers have found that the Kd of PSA to immobilized monoclonal 
antibody on a diagnostic chip is 1.1 ± 0.2 nM, giving us a metric by which to assess the binding 
affinity of our system.7 In addition, researchers also identified a concentration of PSA (2.6 
ng/mL to 4.0 ng/mL) which detects the presence of small prostate cancer without over-
diagnosing patients.7 This range is a design specification necessary for the synthetic antibody to 
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achieve target specificity and sensitivity to PSA. Together, these results will determine whether 
the synthetic antibody is a viable alternative to monoclonal antibodies. 
 
Critiques of Current Literatures and Technologies      
Monoclonal antibodies are extensively used in research.1 However, there are many disadvantages 
of using monoclonal antibodies, including the use of animals, a long manufacturing process and 
high production costs.1 Antibody production is stimulated in animal immune systems by 
injecting them with the target antigen.5 Once the animal’s B-cells start producing antibodies 
specific to the antigen, the B-cells are harvested.5 In order to scale up antibody production, the 
B-cells are combined with an immortal cell line.5 The resulting mass production of antibodies is 
homogenous and pure.5 This entire process can take months to accomplish and is associated with 
significant production costs.5 As a result, this leads to increased medical expenses for consumers 
and limits accessibility to these technologies.11 In addition, the use of animals raises many ethical 
dilemmas and therefore is highly debated in scientific research.11 
 
The primary alternative to monoclonal antibodies is polyclonal antibodies, which have the same 
structure and specificity as monoclonal antibodies while requiring less time, skill, and money to 
produce.1 However, because they still are produced in animals, they have the same ethical 
concerns as monoclonal antibodies.1 In addition, polyclonal antibodies derive from several 
different animals and B cell lines at different time points, resulting in batch-to-batch variation 
not present in monoclonal antibodies, which stem from a single cell line and are therefore more 
consistent.1  
 
Among the other alternatives to monoclonal antibodies scientists are currently developing is 
protein scaffolds.12 Protein scaffolds have a general protein framework with specific peptides or 
amino acids, which give them specificity to a target, incorporated in them.12 These scaffolds can 
be diverse in size, folding, and method of interaction with their targets, giving them more 
flexibility than antibodies, which have a constant structure.12 However, because there is very 
little data on their immunogenicity and degradability in biological fluids, their potential 
applications are currently limited.12 
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Another alternative to monoclonal antibodies currently being explored is aptamers.13 Aptamers 
are strands of DNA or RNA which are selected from large libraries to be specific to a certain 
target.13 Because they involve no animal use, they avoid the ethical issues of monoclonal 
antibodies.13 In addition, because they are made of DNA or RNA, they are more stable than 
antibodies when being stored.13 However, aptamers are known to degrade quickly when exposed 
to nucleases in biological fluid, limiting their potential applications, particularly for 
therapeutics.13 
 
Project Objectives     
Based on the strengths and drawbacks of monoclonal antibodies, the overall goal of this project 
was established to be designing an alternative that maintained the strengths of monoclonal 
antibodies while avoiding their drawbacks as much as possible. The final project objective was 
to develop a cost-effective, ethical alternative to monoclonal antibodies that is easier and faster 
to manufacture with comparable quality: specificity, sensitivity, and binding strength. 
 
Overall Design  
To meet the project objectives, a synthetic antibody produced in E. coli was designed. By being 
produced in E. coli, the synthetic antibody has a lower cost, shorter, and more ethical production 
process than that of monoclonal antibodies.5,11 The physical design of the synthetic antibody 
contains four components: peptide, L-DOPA unnatural amino acid, GFP reporter protein, and 6-
His purification tag (See Figure 3). 
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Figure 3. Synthetic Antibody Detection and Binding of PSA. 
Components of the synthetic antibody include peptide (red), L-DOPA unnatural amino acid (black/red), green 
fluorescent protein (green), 6-His tag (purple). Exposure of synthetic antibody-PSA complex to sodium periodate 
(detection) allows for formation of a covalent bond (pink) between them. 
 
The 15-amino-acid experimental peptide was designed by a previous Senior Design group, 
Therriault and Evans.14 Using open source software developed by University of California, San 
Francisco, called Chimera, a library of peptides was screened using several parameters.14 These 
parameters include electrostatic interactions and predicted binding affinity that were determined 
using the known active site where a commercially available monoclonal PSA antibody binds to 
PSA.14 The top peptide candidate that was screened was selected as the experimental peptide for 
the design.14 The peptide therefore is predicted to give the synthetic antibody high specificity to 
PSA.14 
 
The unnatural amino acid, L-DOPA, was added to the end of the peptide sequence. As discussed 
in the literature review, this unnatural amino acid is capable of performing a redox reaction that 
creates a covalent bond when exposed to sodium periodate.3 When incorporated into the 
synthetic antibody, this covalent bond is expected to form between the synthetic antibody and 
PSA once the peptide has specifically targeted the active site of PSA and sodium periodate is 
added.3 This covalent bond greatly increases the binding strength of the synthetic antibody to 
PSA.3 In order to incorporate this unnatural amino acid, a plasmid designed by Wang et al., 
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pAC-DHPheRS-6TRN, will be transformed into the E. coli with the synthetic antibody 
plasmid.17 This plasmid contains the genetic code for the mutant tRNA and tRNA synthetase 
necessary for unnatural amino acid incorporation.17 
 
GFP was added to the synthetic antibody sequence after the unnatural amino acid. GFP is a 
commonly used reporter protein in research applications because of its simple visualization 
process requiring only UV light.19 It therefore is used to visualize when and how much synthetic 
antibody is present during detection. GFP’s straightforward visualization process was also taken 
advantage of to verify synthetic antibody expression, as its characteristic green fluorescence is 
visible in E. coli correctly producing the synthetic antibody. 
 
The final component of the synthetic antibody, the 6-His tag, was a sequence of six consecutive 
histidines at the end of the synthetic antibody sequence. This 6-His sequence is well-established 
in the scientific community because its unlikelihood of occurring naturally in another E. coli 
protein makes it unique to the protein of interest and therefore ideal for targeting in protein 
purification.20 This sequence therefore allows the synthetic antibody to be purified from the E. 
coli using affinity chromatography that targets this 6-His tag. 
 
The synthetic antibody sequence was designed so that the ribosomes in the E. coli would first 
translate the peptide, followed sequentially by L-DOPA, GFP, and the 6-His tag. This design 
allows the ribosome to incorporate the unnatural amino acid, which stresses the ribosome more 
than natural amino acid incorporation, before translating the long GFP sequence.21 It has been 
hypothesized that translating GFP stresses the ribosome because of its length, and therefore 
makes the ribosome more prone to translation errors.21 Because of the expected crucial nature of 
the unnatural amino acid to the binding strength, and therefore effectiveness, of the synthetic 
antibody, the antibody was designed to minimize the chance of error in unnatural amino acid 
incorporation caused by ribosomal stress.  
 
The synthetic antibody sequence was cloned into the pET-28b vector, which then was 
transformed into TOP10 competent E. coli cells. The pET-28b vector includes a lac operon and 
T7 promoter that allow for regulated expression.14 It also includes a Kan resistance gene which 
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allows for selection of E. coli successfully transformed with this vector.14 Co-transformed into 
the E. coli was the second plasmid, pAC-DHPheRS-6TRN (See Appendix A). This plasmid 
contains a Tet resistance gene used for selection of E. coli that have been successfully 
transformed with this second plasmid.14 Therefore, cells were grown in the presence of both Kan 
and Tet in order to select for cells which have been successfully transformed with both plasmids. 
        
Milestones & Expected Results 
The first milestone of the project is correct plasmid design. This plasmid provides the E. coli 
with the DNA sequence necessary to successfully produce the synthetic antibody. The final 
design must incorporate the sequence for all four components of the synthetic antibody adjacent 
to a promoter in the pET-28b vector to allow the E. coli to produce the synthetic antibody (See 
Appendix B).  
 
The second milestone of the project is successful cloning and transformation. Here, the complete 
synthetic antibody sequence must be incorporated into the pET-28b vector at the correct location 
so that the cells transformed with these plasmids will be able to produce the synthetic antibody. 
The E. coli must then successfully be transformed with this plasmid and the pAC-DHPheRS-
6TRN plasmid in order to begin producing the synthetic antibody. 
 
Once the E. coli have been successfully transformed with the two plasmids, the third milestone 
of the project is successful expression of the synthetic antibody by E. coli. As mentioned in the 
literature review, there are several previously established methods of expression of proteins 
similar to that designed in this project. All were performed and tested while developing a 
successful expression protocol for the synthetic antibody. 
 
After confirming expression, the next milestone is successful purification of the synthetic 
antibody. In order to reach a high standard of purity that is comparable to that of monoclonal 
antibodies, the synthetic antibody must be purified from all other proteins and other materials 
within the E. coli which is producing it. The effectiveness of the purification must be tested, 
optimized, and ultimately confirmed to ensure this high level of purity. 
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The final milestone of the project is testing of the synthetic antibody. In order to be comparable 
to monoclonal antibodies, and therefore a viable alternative, the synthetic antibody must either 
meet or exceed the standards of binding strength, specificity, and sensitivity set by monoclonal 
antibodies. As described in the literature review, these standards for the anti-PSA monoclonal 
antibody are well established, and therefore can be used to test and confirm the efficacy of the 
synthetic antibody.  
 
Team Management           
To maintain accountability and efficiency throughout the project, various responsibilities were 
delegated among the team. Tracy is the liaison with the School of Engineering, handles team’s 
finances, and acts as scribe during team and advisory meetings. She is also responsible for 
ensuring any deadlines are met. Elizabeth coordinates both meeting and laboratory scheduling 
for team and facilitates communications with the advisor, Dr. Zhang. Casey supervises all 
writing and editing for the final report and communicates with industry contacts. The laboratory 
work, report writing, and presentation development was divided equally among team members.  
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Chapter 1: Vector Design & Cloning 
 
 
Introduction  
In designing the cloning of the synthetic antibody sequence into the vector, the synthetic 
antibody sequence must incorporate restriction sites that match ones at specific sites in the vector 
in order to localize the synthetic antibody sequence near the promoter. 
 
Because there is a Kan resistance gene included in the vector, it is expected that cells which have 
been successfully transformed with the pET-28b vector will be resistant to Kan. Of the cells 
which are resistant to Kan, some will be selected for DNA sequencing, which will confirm that 
the cloning of the synthetic antibody sequence into the vector was successful. 
 
Back-up Plan 
If cloning is not accomplished in the allotted time, the oligonucleotide sequences will be sent to a 
company to be cloned into pET28b.  
 
Design Logic and Reasoning 
Peptide Design 
Two sets of forward and reverse single-stranded oligonucleotides of the peptide fragments 
coding for the synthetic antibody and negative control were purchased from BioBasic. One set of 
oligonucleotides has the amber stop codon (TAG) sequence which would allow for successful 
unnatural amino acid incorporation while the other set has a codon for alanine (GCG) in place of 
the TAG sequence, serving as the negative control (See Figure 4). This negative control, which 
besides this one amino acid is identical to the experimental synthetic antibody, will be used 
during the testing phase to confirm that L-DOPA has been incorporated and is increasing the 
binding strength of the synthetic antibody as expected. The forward and reverse oligos were 
constructed to have 17 overlapping nucleotides to optimize annealing efficiency and specificity. 
Each set of oligonucleotides (experimental (TAG) and control (GCG)) were annealed together to 
form two double-stranded fragments. Then the double-stranded fragments were extended into 
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complete inserts through a klenow reaction. The klenow reaction was selected over a PCR 
reaction due to its high efficiency of extension for short fragments such as this peptide, which is 
less than 150 base pairs.  
 
 
Figure 4. Experimental and control nucleotide design sequence alignment. Experimental sequence is specific for 
PSA and contains 3’ TAG codon for L-DOPA incorporation. Control peptide serves as a negative control for L-
DOPA incorporation and contains a codon for alanine. 
 
Expression Vector Selection 
pET28b-GFP was selected as the expression vector because it contains an enhanced GFP. It also 
contains a 6-His that will be used during protein purification by affinity chromatography. The 
oligonucleotides were cloned on the 3’ end of the T7 promoter and 5’ of the 6-His and GFP (See 
Figure 5).  
 
Figure 5. Step-by-step of double digestion of vector to insert peptide. 
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Materials and Methods 
 
pET28b-PI-TAG-GFP Vector Construction 
The peptide predicted to be specific for PSA was selected through an in silico screen as 
described by Therriault and Evans.1 Oligonucleotides containing experimental or control 
peptides, restriction sites, and flanking sequences were ordered as two overlapping fragments 
(BioBasic), annealed, and extended using the large polymerase I, large (klenow) fragment for 15 
minutes at 25℃ (NEB, See Appendix E Table 1). Products were run on a 2% agarose gel for 
verification. Oligonucleotides were purified by QIAquick PCR Purification Kit (Qiagen) and 
double digested with restriction endonucleases EcoRI-HF and XbaI (NEB) for 10 hours at 37℃ 
(See Appendix E Table 2). Products were purified (Qiagen) prior to ligation. 
 
pET28b-GFP contains a 6-His and genes for Kan resistance and GFP. 5 mL cultures were grown 
in LB (Teknova) with 50 μg/mL Kan (Teknova) and plasmids were purified by QIAprep Spin 
Miniprep Kit (Qiagen). Plasmids were double digested for four hours at 37℃ (See Appendix E 
Table 3) and run on 1% agarose gel, gel extracted, and purified using the QIAquick Gel 
Extraction Kit (Qiagen). 5’ DNA ends were dephosphorylated using CIP (NEB, See Appendix E 
Table 4) and subsequently purified (Qiagen) prior to ligation in order to minimize self-ligation of 
the vector without incorporation of the insert. 
 
Ligations (one set for each the control and experimental oligonucleotides) were performed using 
T4 DNA Ligase (Promega) at 1:1, 1:2 and 1:10 ratios of pET28b-GFP:oligonucleotide (See 
Appendix E Table 5) and transformed into TSS TOP10 chemically competent cells (as described 
in Chung et al.) before being plated onto LB-agar (MP Biomedicals LLC) plates containing 50 
µg/mL Kan.15 Colonies were picked and grown in 5 mL LB + 50 µg/mL Kan cultures. DNA was 
purified (Qiagen) and sequenced (Sequetech) using the T7 primer. 
15 
 
Results  
 
Figure 6. 1% agarose gel for pET28b-GFP vector cut (left two bands) and uncut (right band) by EcoRI-HF 
and Xba1 restriction enzymes. Visualized using Fisher Scientific Transilluminator and 0.5 µg/mL EtBr. Ladder 
(far right) was Quick-load 1kb DNA ladder (NEB). 
16 
 
 
Figure 7. Sequence Alignment of Experimental (Query) and Control (Sbjct) Vectors. Highlighted in red is the 
one amino acid difference between the two sequences. 
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Figure 8. Chromatograms of Experimental (A) and Control (B) sequences at location of the amino acid 
difference. 
 
Discussion 
As seen in Figure 6, the vector was successfully double digested, however after sending the 
vectors to sequencing after cloning, the vectors were confirmed to have self-ligated instead of 
incorporating the peptide and L-DOPA. Varied time and order of digestion, and time of CIP 
reaction were performed. Unfortunately, due to time constraints, the designed vectors (one for 
control and one for experimental) were constructed at Epoch Life Science, Inc (Missouri City, 
TX). The vectors were sequenced and results are shown in Appendix C and Appendix D. Figure 
7 shows the nucleotide alignment between the experimental and control vector sequence to 
verify they are correct and differ at the last codon of the peptide. Figure 8 shows the 
chromatogram of both the experiment and control peptides. The little background noise and 
clean peaks show the clones are correct and pure. The confidence that the vectors are pure and 
accurate is necessary before moving on to the next step of the project, synthetic and control 
antibody expression. 
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Chapter 2: Protein Expression 
 
 
Introduction  
In order to maximize efficiency of transformation, a stepwise transformation was performed, 
with cells successfully transformed with one plasmid then being made competent before being 
transformed with the second plasmid (See Figure 9). The pAC-DHPheRS-6TRN plasmid was 
transformed into E. coli first to increase transformation efficiency and minimize toxicity 
concerns caused by the mutant tRNA and tRNA synthetase. In addition, transformation of the 
pAC-DHPheRS-6TRN plasmid first allows for the potential future creation of a commercialized 
kit, containing competent cells into which a plasmid for any synthetic antibody containing L-
DOPA can be transformed and immediately expressed.  
 
 
Figure 9. Sequential co-transformation of pET28b+P1+GFP and pAC-DHPheRS-6TRN 
 
In this step, confirmation of successful expression is performed by taking advantage of the 
design of the synthetic antibody. Because the design includes GFP, cells which are successfully 
producing synthetic antibody are expected to have a visual green fluorescence in the culture. 
Therefore, during expression of the synthetic antibody, the E. coli cultures were observed under 
UV light to confirm that there is this indicative green fluorescence. 
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Back-up Plan 
Although there are a few different aspects of expression where issues may arise, the methods of 
this project were designed to minimize those risks. In order to ensure expression, three different 
established L-DOPA protein expression methods were separately used to optimize yield and 
expression.3,16,17 Since L-DOPA is easily oxidized, the pH was carefully controlled during 
expression. As discussed previously, expression of proteins with unnatural amino acids can result 
in truncated protein. Since GFP is at the carboxy terminus of the synthetic antibody, a truncated 
synthetic antibody would not fluoresce during expression. An intein protein could be attached to 
minimize truncation.10 If these issues or others are experienced and not resolved in a timely 
manner, the experimental and control synthetic vectors will be sent to a company to be 
expressed. 
 
Materials and Methods  
pAC-DHPheRS-6TRN Competent Cell Preparation 
pAC-DHPheRS-6TRN contains genes for the mutant tRNA and mutant tRNA synthetase as well 
as the Tet resistance gene. pAC-DHPheRS-6TRN was transformed into calcium chloride 
competent TOP10 E. coli cells using a high efficiency chemical transformation protocol (NEB). 
Cells were plated on LB-agar + 10 µg/mL Tet (Teknova). A single colony was picked and grown 
in LB broth + 10 µg/mL Tet and a glycerol stock was prepared. Chemically competent cells from 
this glycerol stock were made using the TSS protocol.15 
 
Co-Transformation of pET28b-PI-TAG-GFP 
5 mL cultures of pET28b-PI-TAG-GFP and pET28b-PI-GCG-GFP (Epoch Life Science, Inc) 
were grown overnight before plasmids were purified (Qiagen) and transformed into pAC-
DHPherRS-6TRN TOP10 competent E. coli cells and plated on LB-agar + 30 µg/mL Kan + 25 
µg/mL Tet plates.  
 
Antibody Expression Protocol #1  
This method was adapted from Zhang et al.16 Co-transformed colonies (4 from TAG, 4 from 
GCG) were picked from LB-agar (Teknova, MP Biomedicals LLC) plates and grown in 2.0 mL 
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LB + 30 µg/mL Tet and 60 µg/mL Kan, shaking in the dark at 37℃ overnight. 25% glycerol 
stocks were made for each cell line and stored at -80℃. 500 µL of overnight culture was added 
to 125 mL of M9 Medium Broth (Amresco) with 30 µg/mL Kan + 25 µg/mL Tet and 1 mM L-
DOPA (Sigma-Aldrich) and grown in the dark in a shaking incubator at 37℃ until OD600 
reached 0.5. The pH of the culture was maintained at pH 6.5 during growth. At OD600 0.5, 0.2% 
L-Arabinose (Sigma-Aldrich) was added and cultures were grown for 4 hours at 37℃. Cultures 
were harvested by centrifuge at 5,000 x g for 11 minutes at 4℃, supernatant was decanted and 
pellets were stored at -80℃. 
 
Antibody Expression Protocol #2  
This method was adapted from Wang et al.17 Co-transformed colonies (4 from TAG, 4 from 
GCG) were picked from LB-agar plates and grown in 2.0 mL LB + 30 µg/mL Tet and 60 µg/mL 
Kan, shaking in the dark at 37℃ overnight. 25% glycerol stocks were made for each cell line and 
stored at -80℃. 500 µL of overnight culture was added to 125 mL of M9 Medium Broth with 30 
µg/mL Kan + 25 µg/mL Tet and 1 mM L-DOPA (Sigma-Aldrich) and grown in the dark in a 
shaking incubator at 37℃ until OD600 reached 0.5. The pH of the culture was maintained at pH 
6.5 during growth. At OD600 0.5, 1 mM IPTG was added and cultures were grown for 5 hours at 
37℃. Cultures were harvested by centrifuge at 5,000 x g for 11 minutes at 4℃, supernatant was 
decanted and pellets were stored at -80℃.  
 
Antibody Expression Protocol #3  
This method was adapted from Umeda et al.3 Co-transformed colonies (4 from TAG, 4 from 
GCG) were picked from LB-agar plates and grown in 2.0 mL LB + 30 µg/mL Tet and 60 µg/mL 
Kan, shaking in the dark at 37℃ overnight. 25% glycerol stocks were made for each cell line and 
stored at -80℃. 500 uL of overnight culture was added to 125 mL of M9 Medium Broth with 30 
µg/mL Kan + 25 µg/mL Tet and grown in the dark in a shaking incubator, at 37℃ until OD600 
reached 0.6. During this time, the pH of the culture was maintained at pH 6.5. At OD600 0.6, 1 
mM IPTG was added to the cultures, which then were incubated at 30℃ for 6 hours. Cultures 
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were viewed after 4 hours using a Fisher Scientific Transilluminator. Cultures were harvested by 
centrifuge at 5,000 x g for 11 minutes at 4℃, supernatant was decanted and pellets were stored at 
-80℃. 
 
Results  
Co-Transformation of pET28b+PI+TAG and pAC-DHPheRS-6TRN 
 
Figure 10. Transformed E. coli + pAC-DHPheRS-6TRN plated on LB + agar + 10 µg/mL Tet+ 50 µg/mL Kan 
+ 0.2% arabinose. TOP10 E. coli + pAC-DHPheRS-6TRN transformed with experimental synthetic antibody 
plasmid (A), control synthetic antibody plasmid (B), no plasmid (C), plasmid with no synthetic antibody (D).  
 
Figure 11. Experimental (A), control (B), and no GFP (C) cultures using antibody expression protocol #3 
visualized under UV light after 4 hours of synthetic antibody expression. 
 
Discussion  
As shown in Figure 10, the co-transformation of pET28b+PI+TAG and pET28b+PI+GCG 
(control) into TOP10 competent cells containing pAC-DHPheRS-6TRN was successful. Plates C 
and D serve as negative controls. Plate C was plated with cells transformed with water and plate 
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D was plated with cells transformed with a plasmid without Tet resistance, a quality control for 
the plates.  
 
For the cultures using expression protocol #3, the cultures were placed in UW light 4 hours after 
induction of synthetic antibody production with IPTG (Figure 11). Compared to the culture with 
cells not producing the synthetic antibody, which therefore were not producing GFP, the 
experimental and control cultures had a distinct green color under the UV, indicating that they 
were producing GFP and therefore the synthetic antibody. These results indicate successful 
expression of the synthetic antibody within the E. coli cells. 
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Chapter 3: Protein Purification  
 
 
Introduction  
Before testing the functionality of the synthetic antibodies, they must first be purified. This was 
done by manual affinity chromatography using 6-His. After lysing the cells, the proteins were 
separated and passed through a column containing Ni-NTA beads. Only the synthetic antibody 
will bind to the beads allowing for the other proteins to be removed. The synthetic antibody was 
then eluted as a pure sample from the beads. 
 
Back-up Plan  
Although manual affinity chromatography is a well-defined purification procedure, if any issues 
arise, FPLC will be used. This automated process produces pure and large quantities of proteins. 
However, it would be time consuming to troubleshoot and learn how to use this machine. 
Purification can also be contracted out to a company if necessary.   
 
Materials and Methods  
A separate purification was performed for each individual cell type and growing condition. E. 
coli pellets were thawed in a hot water bath for approximately 10 minutes. Each pellet was then 
resuspended in 5 mL of lysis buffer (PBS + 1 mg/mL lysozyme + 0.5 mM PMSF + 10 mM 
imidazole) and left on ice for 20 minutes. The cells were then sonicated 6 times at 30% 
alternating between 6 seconds on and 6 seconds off. The lysate was then centrifuged at 4℃ and 
16,000 rpm for 40 minutes. 1 mL sample of the supernatant was taken and stored in -20℃. 
 
While centrifuging, one set of HisPurTM Ni-NTA beads (Thermo Fisher Scientific) specific to 
the 6-His tag was prepared for each culture by resuspending 125 µL of the beads (1:1000 ratio of 
volume of beads:volume of initial culture) in 5 mL of PBS + 25 mM imidazole before being 
centrifuged for 4 minutes at 2000 rpm. After pouring out the supernatant, this process was 
repeated 4 times. 
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The supernatant of the centrifuged lysate solutions was then used to resuspend the Ni-NTA beads 
(one culture per set of beads). Binding of the proteins to the beads was then done by rocking the 
resuspended beads at 4℃ for 1 hour before centrifuging them for 4 minutes at 2000 rpm at 4℃. 
1 mL of the flow-through after binding was then sampled and the rest was discarded. The beads 
were then washed 5 times. In these wash steps, the beads were resuspended in PBS + 25 mM 
imidazole wash buffer, rocked for 20 minutes at 4℃, then centrifuged at 2000 rpm at 4℃ for 4 
minutes before the supernatant was sampled and discarded. 
 
For elution, the beads were resuspended in 200 µL of PBS + 250 mM imidazole, rocked for 20 
minutes, and centrifuged at 2000 rpm for 4 minutes. The supernatant, which ideally contains the 
target protein, was then extracted and stored at -20℃. Two elution steps were performed for each 
culture. 
 
Samples of lysate, flow-through, initial wash step, and elution for each purification were run on a 
SDS-PAGE (Genscript) at 120 volts for 60 minutes. Gels were visualized and imaged using 
LabSafe GEL Blue (G-Biosciences). 
 
Results  
 
Figure 12. SDS-PAGE of purification Left image shows synthetic antibody and right shows control antibody. Lane 
one is PageRuler Prestained Protein Ladder (ThermoFisher Scientific). Lane two is sample of supernatant after cells 
were lysed and centrifuged. Lane three is flow-through sample after binding to column. Lane four is sample after 
first wash is performed. Lane five is sample of first elution. 
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Discussion  
Both the control and experimental SDS-PAGEs show a large amount of proteins of many sizes in 
the supernatant lane, which is expected as this was a sample of all of the proteins in the E. coli. 
Many of these proteins did not bind to the beads and were therefore also in the flow-through, 
which would also be expected because the Ni-NTA HisPur beads which were used were specific 
to the 6-His unique to the synthetic antibody, preventing other proteins without this tag from 
binding. The wash lanes indicate that there was some nonspecific binding of non-synthetic 
antibody proteins to the beads, which were then removed by the wash steps as the higher 
concentration of imidazole allowed it to competitively bind to the beads.  
 
The elution lanes show a strong band at approximately 27 kDa, which is the predicted size of our 
synthetic antibody. Therefore, the antibody has essentially been purified. However, there are 
some remaining bands of various weights shown in the elution lanes, indicating that there is still 
some non-specific binding occurring, which would need to be eliminated through optimization of 
the protein purification protocol. This optimization would most likely involve adjustments in the 
wash steps, such as increasing the concentration of imidazole (increasing its ability to compete 
with other proteins to bind to the beads) or a greater number of washes.  
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Chapter 4: Conclusion 
 
Testing & Analysis 
The next steps of this project will be to analyze the functionality of the synthetic antibody. To 
replace the monoclonal antibody used for PSA detection, the synthetic antibody must have 
comparable functionality. The previous results show the experimental and control synthetic 
antibodies were correctly expressed. Next, the synthetic antibodies will be tested to ensure 
proper L-DOPA incorporation in the experimental synthetic antibody. This will be done by 
measuring the Kd of both synthetic antibodies to PSA using ITC. The Kd value will indicate the 
binding affinity between the synthetic antibody and PSA. Since the incorporation of L-DOPA 
allows the experimental synthetic antibody to form a covalent bond to PSA, the binding strength 
will be much greater than the control synthetic antibody. The values will also be compared to the 
binding strength of the currently used monoclonal antibody for PSA detection, 1.1 ± 0.2 nM. The 
experimental synthetic antibody must have, at most, the same Kd value to be comparable to the 
anti-PSA monoclonal antibody.  
  
Others metrics that will be tested and compared to those of the anti-PSA monoclonal antibody 
are specificity and sensitivity. It is crucial that the synthetic antibody is specific to PSA so that 
prostate cancer detection tests are precise and accurate. Both specificity and sensitivity will be 
tested using a Western blot. PSA samples will be titrated; then the specificity and sensitivity of 
the experimental synthetic antibody will be measured and compared to the anti-PSA monoclonal 
antibody. Currently, levels of PSA below 2.5 ng/mL are considered to be within the normal 
range.7 Blood concentrations of PSA between 2.5 ng/mL and 4.0 ng/mL are an indication of 
prostate cancer.7 The synthetic antibody must be able to clearly indicate the differences between 
these two ranges.  
  
The design of the synthetic antibody predicts the specificity, sensitivity, and binding strength to 
be at least as effective, if not better than, the standards set by the currently used anti-PSA 
monoclonal antibody. However, these specifications must be tested to ensure incorporation of L-
DOPA during expression and comparable functionality to currently used technologies. 
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Summary and Future Applications 
This project focuses on creating a synthetic antibody for PSA measurement for prostate cancer 
detection. If testing follows theoretical values, this antibody can replace the currently used anti-
PSA monoclonal antibody. As previously mentioned, antibodies are used extensively in research 
and medicine and prostate cancer detection is just one of numerous applications. This project 
evaluates the synthetic antibody design as a possibility to replace other monoclonal antibodies. 
Synthetic antibodies avoid many of the drawbacks of monoclonal antibodies, including batch-to-
batch variability, ethical concerns, and an expensive and long production process.1  
  
The results from this project show successful design and cloning of the synthetic antibody. In 
addition, it was successfully and produced in and purified from E. coli. Future testing would 
verify the incorporation and functionality of the synthetic antibody compared to the currently 
used monoclonal antibody for prostate cancer detection. This proof of concept is a model for 
future synthetic antibodies to be produced to essentially any other protein target. The advantages 
of this modular synthetic antibody design would make it desireable to researchers as well as 
clinicians and could become the new gold standard antibodies in industry. From the results 
obtained from this project, synthetic antibodies for diagnostic and therapeutic purposes are a 
promising technology, however, future testing is still required.    
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Chapter 5: Ethical Concerns 
 
Monoclonal antibodies are currently widely used in both industry and research settings, and as a 
result, they are an established and well-known product due to their high specificity and binding 
strength. However, the production process of the monoclonal antibodies has two main ethical 
concerns including animal use as well as the expensive nature of the process leading to concerns 
regarding fair access of patients to medical advancements.   
 
The use of live animals such as mice and rabbits as a hosts of production of monoclonal 
antibodies is an ethical concern because it requires invoking their immune system prior to the 
extraction of their blood. This process is harmful to the animals and raises concerns regarding 
animal abuse. Overall, the use of animals as hosts for this production method is life-threatening 
to the animals and usually leads to their death. In comparison, synthetic antibodies do not use 
animals such as mice and rabbits as hosts, instead E. coli bacteria are used.  
 
Another ethical concern to monoclonal antibodies is their high cost as a result of their production 
process. The high cost of this technology can lead to minimal access to those who cannot afford 
to have access to it. Monoclonal antibodies are extensively used in research for medical 
advancements that could benefit patients, and the high-cost can deter researchers from using it 
and can lead to delays in new technology. Similarly, monoclonal antibodies are used in prostate 
cancer blood test and their high cost increases the cost of the test. In response, health insurance 
companies are reluctant to pay for it if the patient does not show any signs of prostate cancer. It 
is necessary for these tests to be done early regardless of symptoms because the lack of early 
detection contributes to many cancer patient deaths.    
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Chapter 6: Engineering Standards and Realistic Constraints 
 
For all engineering designs, there are many considerations that must be taken into account prior 
to creating and implementing the design. The following factors will be discussed in terms of how 
the design and stakeholders that are involved will be impacted.  
 
Economic 
Like any other product, economic factors are necessary to take into consideration in terms of 
how much resources are needed to fund as well as implement the design and the overall cost of 
the product for it to be used by its intended audience. For this design, it was necessary to propose 
a budget for funding that was enough to carry out all of the experiments. Typical antibody 
production requires an immense amount of resources as well as animal facilities which can drive 
up costs and increase the amount of labor that is needed. Instead, the synthetic antibody 
production is performed at a smaller scale for testing and the host that is used for production, E. 
coli, is much cheaper and easier to scale up. Not only for the practicality of this project, but for 
future implementation, the synthetic antibody design described in this paper is a cheaper 
alternative than commercial monoclonal antibody production which will benefit researchers and 
patients who would have increased accessibility due to the lower cost of this technology.  
 
Ethical 
There are many ethical concerns with regards to who the stakeholders of this project will be. 
These stakeholders include who will be producing the synthetic antibody, who will be using the 
synthetic antibody such as researchers, academic institutions, and industry members, and lastly 
who would be benefitting or affected by the technology that is developed either from the indirect 
or direct usage of the synthetic antibody. As elaborated in Chapter 5, there are ethical concerns 
with regards to animal production as well as high costs that would limit the accessibility to the 
benefits of this technology. For this design, there are no animals used in the production process 
and the overall production is much cheaper than the commercial production methods currently 
used. As a result, this would eliminate ethical conflicts for those who are working to produce the 
30 
 
synthetic antibody, those who are concerned about animal mistreatment, and those who would be 
deterred from using antibodies due to their high costs.  
 
A big-picture concern of this design could be if it is used a biological weapon due to the ease of 
the design. The screening method could be used to screen for a peptide that can target and cause 
disease or a physiological disorder. Then it could be implemented and produced using the 
production method described in this paper in a small laboratory setting without any regulations. 
It is necessary to be aware of this ethical concern; however, the screening process as a well as 
weaponizing of the synthetic antibody requires extensive knowledge that is not as straight-
forward as the application of the design in this paper which is to target PSA, a well-known 
biomarker. However engineering as well as ethical standards should be upheld by those who are 
producing it to cause no harm to any of the stakeholders.  
 
Social 
Social responsibility towards all stakeholders is necessary to be taken into consideration for this 
project. Stakeholders who have limited access to the benefits of monoclonal antibody technology 
are those who are financially deterred as a result of high prices that would prevent insurance 
companies from subsidizing the cost of the application such as prostate cancer blood tests. A 
method that could allow for equal access to synthetic antibody is by reducing the overall cost of 
it. For example if the synthetic antibody is used for drug development, it would substantially 
reduce the cost of research due to failed attempts or multiple iterations that are required during 
development. This would lead to a reduced cost of the drug, and would allow for increased 
access to it for those who previously did not have access due to its high cost.  
 
Manufacturability 
For almost all designs, it is necessary that the design is validated to work on a smaller-scale 
before scaling it up in order to conserve resources. However, scaling-up can lead to other 
challenges and complications. One of the challenges of monoclonal antibody production is that 
scaling-up requires larger animal facilities, and there is also a potential for variations as a well as 
functionality in the final product due to it coming from multiple animal hosts.14 This can lead to 
inconsistencies in quality control.14     
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This manufacturability concern can be overcome in the synthetic antibody design because the 
production platform is E. coli rather than multiple animal hosts. Scaling-up with E.coli using 
bioreactors has been documented in literature and has been well-studied so this design has a very 
real potential for scaling-up to the level of commercial usage with consistent quality.18  
 
Health & Safety 
It is necessary to ensure the health and safety of not only the members of this project but also 
other stakeholders who would be using this product. To produce the synthetic antibody, all 
members of the team were qualified to work in the lab by undergoing an exam to ensure that 
Santa Clara University Laboratory Safety Protocol and Procedures were understood. All 
members have also previously worked on protein production and purification and so proper lab 
techniques as well as handling of hazardous material have been established, and as a result, 
safety in the lab for all members can be ensured.  
 
For the stakeholders who would be using the product it is necessary that it is appropriately used 
for its intended purpose. An example of this would be to use the prostate specific synthetic 
antibody for the purpose of detection of PSA rather than for detecting another biomarker. This 
will ensure safety and accuracy for the patients who would be receiving the results. 
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Appendix 
 
Appendix A: pAC DHPheRS-6TRN plasmid map 
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Appendix B: Experimental Vector 
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Appendix C. Experimental Vector: pET28-P1+GFP+His Sequencing 
Information 
LOCUS    GS61233-1 pET28-P1+GFP+His        5977 bp ds-DNA circular SYN 25-Apr-2017 
DEFINITION  . 
ACCESSION   . 
VERSION  . 
KEYWORDS GS61233-1 pET28-P1+GFP+His 
SOURCE   synthetic DNA construct 
  ORGANISM  synthetic DNA construct 
REFERENCE   1  (bases 1 to 5977) 
  AUTHORS   . 
  TITLE     Direct Submission 
FEATURES          Location/Qualifiers 
  source       1..5977 
                  /organism="synthetic DNA construct" 
                  /mol_type="other DNA" 
  terminator   26..73 
                  /note="T7 terminator" 
                  /note="transcription terminator for bacteriophage T7 RNA 
                  polymerase" 
                  /note="color: #ffffff" 
  CDS             complement(140..157) 
                  /codon_start=1 
                  /product="6xHis affinity tag" 
                  /note="6xHis" 
                  /note="color: #cc99b2" 
                     /translation="HHHHHH" 
  gene            173..949 
                     /note="P1+GFP+His" 
                  /note="color: #a6acb3; direction: RIGHT" 
  CDS          complement(179..892) 
                  /codon_start=1 
                  /product="GFP variant optimized for excitation by UV light" 
                  /label="GFPuv" 
                  /note="GFPuv" 
                  /note="color: #05fd14" 
                     /translation="MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK 
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                  FICTTGKLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG 
                     NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKA 
                     NFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLE 
                  FVTAAGITHGMDELYK" 
  protein_bind 952..976 
                  /bound_moiety="lac repressor encoded by lacI" 
                  /note="lac operator" 
                  /note="The lac repressor binds to the lac operator to 
                  inhibit transcription in E. coli. This inhibition can be 
                  relieved by adding lactose or 
                     isopropyl-beta-D-thiogalactopyranoside (IPTG)." 
                  /note="color: #31849b" 
  promoter     complement(977..995) 
                  /note="T7 promoter" 
                  /note="promoter for bacteriophage T7 RNA polymerase" 
                  /note="color: #ffffff; direction: LEFT" 
  promoter     1304..1381 
                  /gene="lacI" 
                  /note="lacI promoter" 
                  /note=" 
                  " 
                  /note="color: #ffffff; direction: RIGHT" 
  CDS          1382..2464 
                  /codon_start=1 
                  /gene="lacI" 
                  /product="lac repressor" 
                  /note="lacI" 
                  /note="The lac repressor binds to the lac operator to 
                  inhibit transcription in E. coli. This inhibition can be 
                  relieved by adding lactose or 
                  isopropyl-beta-D-thiogalactopyranoside (IPTG)." 
                  /note="color: #993366" 
                     /translation="MKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAEL 
                     NYIPNRVAQQLAGKQSLLIGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGV 
                     EACKAAVHNLLAQRVSGLIINYPLDDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSH 
                     EDGTRLGVEHLVALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDWSA 
                     MSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAITESGLRVGADISVVGYDDTEDSSC 
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                     YIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPR 
                  ALADSLMQLARQVSRLESGQ" 
  CDS          3273..3464 
                  /codon_start=1 
                  /gene="rop" 
                  /product="Rop protein" 
                  /note="rop" 
                  /note="color: #993366" 
                     /translation="MTKQEKTALNMARFIRSQTLTLLEKLNELDADEQADICESLHDHA 
                  DELYRSCLARFGDDGENL" 
  rep_origin   complement(3894..4482) 
                  /direction=LEFT 
                  /note="ori" 
                     /note="high-copy-number colE1/pMB1/pBR322/pUC origin of 
                  replication" 
                  /note="color: #ffff00" 
  CDS          4604..5419 
                  /codon_start=1 
                     /gene="aph(3')-Ia" 
                     /product="aminoglycoside phosphotransferase" 
                  /note="KanR" 
                  /note="confers resistance to kanamycin" 
                  /note="color: #ccffcc" 
                     /translation="MSHIQRETSCSRPRLNSNMDADLYGYKWARDNVGQSGATIYRLYG 
                     KPDAPELFLKHGKGSVANDVTDEMVRLNWLTEFMPLPTIKHFIRTPDDAWLLTTAIPGK 
                     TAFQVLEEYPDSGENIVDALAVFLRRLHSIPVCNCPFNSDRVFRLAQAQSRMNNGLVDA 
                     SDFDDERNGWPVEQVWKEMHKLLPFSPDSVVTHGDFSLDNLIFDEGKLIGCIDVGRVGI 
                     ADRYQDLAILWNCLGEFSPSLQKRLFQKYGIDNPDMNKLQFHLMLDEFF" 
  rep_origin   complement(5511..5966) 
                  /direction=LEFT 
                  /note="f1 ori" 
                  /note="f1 bacteriophage origin of replication; arrow 
                  indicates direction of (+) strand synthesis" 
                  /note="color: #ffff00" 
ORIGIN 
     1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa 
    61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt 
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   121 tgttagcagc cggatctcag tggtggtggt ggtggtgctc gagtgcggcc gcaagctttt 
   181 tgtagagctc atccatgcca tgtgtaatcc cagcagcagt tacaaactca agaaggacca 
   241 tgtggtcacg cttttcgttg ggatctttcg aaagggcaga ttgtgtcgac aggtaatggt 
   301 tgtctggtaa aaggacaggg ccatcgccaa ttggagtatt ttgttgataa tggtctgcta 
   361 gttgaacgga tccatcttca atgttgtggc gaattttgaa gttagctttg attccattct 
   421 tttgtttgtc tgccgtgatg tatacattgt gtgagttata gttgtactcg agtttgtgtc 
   481 cgagaatgtt tccatcttct ttaaaatcaa taccttttaa ctcgatacga ttaacaaggg 
   541 tatcaccttc aaacttgact tcagcacgcg tcttgtagtt cccgtcatct ttgaaagata 
   601 tagtgcgttc ctgtacataa ccttcgggca tggcactctt gaaaaagtca tgccgtttca 
   661 tatgatccgg ataacgggaa aagcattgaa caccataaga gaaagtagtg acaagtgttg 
   721 gccatggaac aggtagtttt ccagtagtgc aaataaattt aagggtaagt tttccgtatg 
   781 ttgcatcacc ttcaccctct ccactgacag aaaatttgtg cccattaaca tcaccatcta 
   841 attcaacaag aattgggaca actccagtga aaagttcttc tcctttactc atgaattcct 
   901 agcaggtcca gcaatgatgt tcaatgcaat acgccacgca cattctagag gggaattgtt 
   961 atccgctcac aattccccta tagtgagtcg tattaatttc gcgggatcga gatctcgatc 
  1021 ctctacgccg gacgcatcgt ggccggcatc accggcgcca caggtgcggt tgctggcgcc 
  1081 tatatcgccg acatcaccga tggggaagat cgggctcgcc acttcgggct catgagcgct 
  1141 tgtttcggcg tgggtatggt ggcaggcccc gtggccgggg gactgttggg cgccatctcc 
  1201 ttgcatgcac cattccttgc ggcggcggtg ctcaacggcc tcaacctact actgggctgc 
  1261 ttcctaatgc aggagtcgca taagggagag cgtcgagatc ccggacacca tcgaatggcg 
  1321 caaaaccttt cgcggtatgg catgatagcg cccggaagag agtcaattca gggtggtgaa 
  1381 tgtgaaacca gtaacgttat acgatgtcgc agagtatgcc ggtgtctctt atcagaccgt 
  1441 ttcccgcgtg gtgaaccagg ccagccacgt ttctgcgaaa acgcgggaaa aagtggaagc 
  1501 ggcgatggcg gagctgaatt acattcccaa ccgcgtggca caacaactgg cgggcaaaca 
  1561 gtcgttgctg attggcgttg ccacctccag tctggccctg cacgcgccgt cgcaaattgt 
  1621 cgcggcgatt aaatctcgcg ccgatcaact gggtgccagc gtggtggtgt cgatggtaga 
  1681 acgaagcggc gtcgaagcct gtaaagcggc ggtgcacaat cttctcgcgc aacgcgtcag 
  1741 tgggctgatc attaactatc cgctggatga ccaggatgcc attgctgtgg aagctgcctg 
  1801 cactaatgtt ccggcgttat ttcttgatgt ctctgaccag acacccatca acagtattat 
  1861 tttctcccat gaagacggta cgcgactggg cgtggagcat ctggtcgcat tgggtcacca 
  1921 gcaaatcgcg ctgttagcgg gcccattaag ttctgtctcg gcgcgtctgc gtctggctgg 
  1981 ctggcataaa tatctcactc gcaatcaaat tcagccgata gcggaacggg aaggcgactg 
  2041 gagtgccatg tccggttttc aacaaaccat gcaaatgctg aatgagggca tcgttcccac 
  2101 tgcgatgctg gttgccaacg atcagatggc gctgggcgca atgcgcgcca ttaccgagtc 
  2161 cgggctgcgc gttggtgcgg atatctcggt agtgggatac gacgataccg aagacagctc 
  2221 atgttatatc ccgccgttaa ccaccatcaa acaggatttt cgcctgctgg ggcaaaccag 
  2281 cgtggaccgc ttgctgcaac tctctcaggg ccaggcggtg aagggcaatc agctgttgcc 
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  2341 cgtctcactg gtgaaaagaa aaaccaccct ggcgcccaat acgcaaaccg cctctccccg 
  2401 cgcgttggcc gattcattaa tgcagctggc acgacaggtt tcccgactgg aaagcgggca 
  2461 gtgagcgcaa cgcaattaat gtaagttagc tcactcatta ggcaccggga tctcgaccga 
  2521 tgcccttgag agccttcaac ccagtcagct ccttccggtg ggcgcggggc atgactatcg 
  2581 tcgccgcact tatgactgtc ttctttatca tgcaactcgt aggacaggtg ccggcagcgc 
  2641 tctgggtcat tttcggcgag gaccgctttc gctggagcgc gacgatgatc ggcctgtcgc 
  2701 ttgcggtatt cggaatcttg cacgccctcg ctcaagcctt cgtcactggt cccgccacca 
  2761 aacgtttcgg cgagaagcag gccattatcg ccggcatggc ggccccacgg gtgcgcatga 
  2821 tcgtgctcct gtcgttgagg acccggctag gctggcgggg ttgccttact ggttagcaga 
  2881 atgaatcacc gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg tctgcgacct 
  2941 gagcaacaac atgaatggtc ttcggtttcc gtgtttcgta aagtctggaa acgcggaagt 
  3001 cagcgccctg caccattatg ttccggatct gcatcgcagg atgctgctgg ctaccctgtg 
  3061 gaacacctac atctgtatta acgaagcgct ggcattgacc ctgagtgatt tttctctggt 
  3121 cccgccgcat ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt 
  3181 catcatcagt aacccgtatc gtgagcatcc tctctcgttt catcggtatc attaccccca 
  3241 tgaacagaaa tcccccttac acggaggcat cagtgaccaa acaggaaaaa accgccctta 
  3301 acatggcccg ctttatcaga agccagacat taacgcttct ggagaaactc aacgagctgg 
  3361 acgcggatga acaggcagac atctgtgaat cgcttcacga ccacgctgat gagctttacc 
  3421 gcagctgcct cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg 
  3481 agacggtcac agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgt 
  3541 cagcgggtgt tggcgggtgt cggggcgcag ccatgaccca gtcacgtagc gatagcggag 
  3601 tgtatactgg cttaactatg cggcatcaga gcagattgta ctgagagtgc accatatatg 
  3661 cggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctcttccgct 
  3721 tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac 
  3781 tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga 
  3841 gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat 
  3901 aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac 
  3961 ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct 
  4021 gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg 
  4081 ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg 
  4141 ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt 
  4201 cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg 
  4261 attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac 
  4321 ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga 
  4381 aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt 
  4441 gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt 
  4501 tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaac 
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  4561 aataaaactg tctgcttaca taaacagtaa tacaaggggt gttatgagcc atattcaacg 
  4621 ggaaacgtct tgctctaggc cgcgattaaa ttccaacatg gatgctgatt tatatgggta 
  4681 taaatgggct cgcgataatg tcgggcaatc aggtgcgaca atctatcgat tgtatgggaa 
  4741 gcccgatgcg ccagagttgt ttctgaaaca tggcaaaggt agcgttgcca atgatgttac 
  4801 agatgagatg gtcagactaa actggctgac ggaatttatg cctcttccga ccatcaagca 
  4861 ttttatccgt actcctgatg atgcatggtt actcaccact gcgatccccg ggaaaacagc 
  4921 attccaggta ttagaagaat atcctgattc aggtgaaaat attgttgatg cgctggcagt 
  4981 gttcctgcgc cggttgcatt cgattcctgt ttgtaattgt ccttttaaca gcgatcgcgt 
  5041 atttcgtctc gctcaggcgc aatcacgaat gaataacggt ttggttgatg cgagtgattt 
  5101 tgatgacgag cgtaatggct ggcctgttga acaagtctgg aaagaaatgc ataaactttt 
  5161 gccattctca ccggattcag tcgtcactca tggtgatttc tcacttgata accttatttt 
  5221 tgacgagggg aaattaatag gttgtattga tgttggacga gtcggaatcg cagaccgata 
  5281 ccaggatctt gccatcctat ggaactgcct cggtgagttt tctccttcat tacagaaacg 
  5341 gctttttcaa aaatatggta ttgataatcc tgatatgaat aaattgcagt ttcatttgat 
  5401 gctcgatgag tttttctaag aattaattca tgagcggata catatttgaa tgtatttaga 
  5461 aaaataaaca aataggggtt ccgcgcacat ttccccgaaa agtgccacct aaattgtaag 
  5521 cgttaatatt ttgttaaaat tcgcgttaaa tttttgttaa atcagctcat tttttaacca 
  5581 ataggccgaa atcggcaaaa tcccttataa atcaaaagaa tagaccgaga tagggttgag 
  5641 tgttgttcca gtttggaaca agagtccact attaaagaac gtggactcca acgtcaaagg 
  5701 gcgaaaaacc gtctatcagg gcgatggccc actacgtgaa ccatcaccct aatcaagttt 
  5761 tttggggtcg aggtgccgta aagcactaaa tcggaaccct aaagggagcc cccgatttag 
  5821 agcttgacgg ggaaagccgg cgaacgtggc gagaaaggaa gggaagaaag cgaaaggagc 
  5881 gggcgctagg gcgctggcaa gtgtagcggt cacgctgcgc gtaaccacca cacccgccgc 
  5941 gcttaatgcg ccgctacagg gcgcgtccca ttcgcca 
// 
Appendix D. Control Vector: pET28-P1+GFP+His Sequencing Information 
LOCUS    GS61233-2 pET28-control+GFP+His       5977 bp ds-DNA circular SYN 25-Apr-2017 
DEFINITION  . 
ACCESSION   . 
VERSION  . 
KEYWORDS GS61233-2 pET28-control+GFP+His 
SOURCE   synthetic DNA construct 
  ORGANISM  synthetic DNA construct 
REFERENCE   1  (bases 1 to 5977) 
  AUTHORS   . 
  TITLE     Direct Submission 
FEATURES          Location/Qualifiers 
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  source       1..5977 
                  /organism="synthetic DNA construct" 
                  /mol_type="other DNA" 
  terminator   26..73 
                  /note="T7 terminator" 
                  /note="transcription terminator for bacteriophage T7 RNA 
                  polymerase" 
                  /note="color: #ffffff" 
     CDS          complement(140..157) 
                  /codon_start=1 
                  /product="6xHis affinity tag" 
                  /note="6xHis" 
                  /note="color: #cc99b2" 
                     /translation="HHHHHH" 
  misc_feature 173..949 
                     /note="control+GFP+His" 
                  /note="color: #a6acb3" 
  CDS          complement(179..892) 
                  /codon_start=1 
                  /product="GFP variant optimized for excitation by UV light" 
                  /label="GFPuv" 
                  /note="GFPuv" 
                  /note="color: #05fd14" 
                     /translation="MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK 
                  FICTTGKLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG 
                     NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKA 
                     NFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLE 
                  FVTAAGITHGMDELYK" 
  protein_bind    952..976 
                  /bound_moiety="lac repressor encoded by lacI" 
                  /note="lac operator" 
                  /note="The lac repressor binds to the lac operator to 
                  inhibit transcription in E. coli. This inhibition can be 
                  relieved by adding lactose or 
                     isopropyl-beta-D-thiogalactopyranoside (IPTG)." 
                  /note="color: #31849b" 
  promoter     complement(977..995) 
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                  /note="T7 promoter" 
                  /note="promoter for bacteriophage T7 RNA polymerase" 
                  /note="color: #ffffff; direction: LEFT" 
  promoter     1304..1381 
                  /gene="lacI" 
                  /note="lacI promoter" 
                     /note=" 
                  " 
                  /note="color: #ffffff; direction: RIGHT" 
  CDS          1382..2464 
                  /codon_start=1 
                  /gene="lacI" 
                  /product="lac repressor" 
                  /note="lacI" 
                  /note="The lac repressor binds to the lac operator to 
                  inhibit transcription in E. coli. This inhibition can be 
                  relieved by adding lactose or 
                  isopropyl-beta-D-thiogalactopyranoside (IPTG)." 
                  /note="color: #993366" 
                     /translation="MKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAEL 
                     NYIPNRVAQQLAGKQSLLIGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGV 
                     EACKAAVHNLLAQRVSGLIINYPLDDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSH 
                     EDGTRLGVEHLVALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDWSA 
                     MSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAITESGLRVGADISVVGYDDTEDSSC 
                  YIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPR 
                  ALADSLMQLARQVSRLESGQ" 
  CDS          3273..3464 
                  /codon_start=1 
                  /gene="rop" 
                  /product="Rop protein" 
                  /note="rop" 
                  /note="color: #993366" 
                     /translation="MTKQEKTALNMARFIRSQTLTLLEKLNELDADEQADICESLHDHA 
                  DELYRSCLARFGDDGENL" 
  rep_origin   complement(3894..4482) 
                  /direction=LEFT 
                  /note="ori" 
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                     /note="high-copy-number colE1/pMB1/pBR322/pUC origin of 
                  replication" 
                  /note="color: #ffff00" 
  CDS          4604..5419 
                     /codon_start=1 
                     /gene="aph(3')-Ia" 
                     /product="aminoglycoside phosphotransferase" 
                  /note="KanR" 
                  /note="confers resistance to kanamycin" 
                  /note="color: #ccffcc" 
                     /translation="MSHIQRETSCSRPRLNSNMDADLYGYKWARDNVGQSGATIYRLYG 
                     KPDAPELFLKHGKGSVANDVTDEMVRLNWLTEFMPLPTIKHFIRTPDDAWLLTTAIPGK 
                     TAFQVLEEYPDSGENIVDALAVFLRRLHSIPVCNCPFNSDRVFRLAQAQSRMNNGLVDA 
                     SDFDDERNGWPVEQVWKEMHKLLPFSPDSVVTHGDFSLDNLIFDEGKLIGCIDVGRVGI 
                     ADRYQDLAILWNCLGEFSPSLQKRLFQKYGIDNPDMNKLQFHLMLDEFF" 
  rep_origin   complement(5511..5966) 
                  /direction=LEFT 
                  /note="f1 ori" 
                  /note="f1 bacteriophage origin of replication; arrow 
                  indicates direction of (+) strand synthesis" 
                  /note="color: #ffff00" 
ORIGIN 
     1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa 
    61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt 
   121 tgttagcagc cggatctcag tggtggtggt ggtggtgctc gagtgcggcc gcaagctttt 
   181 tgtagagctc atccatgcca tgtgtaatcc cagcagcagt tacaaactca agaaggacca 
   241 tgtggtcacg cttttcgttg ggatctttcg aaagggcaga ttgtgtcgac aggtaatggt 
   301 tgtctggtaa aaggacaggg ccatcgccaa ttggagtatt ttgttgataa tggtctgcta 
   361 gttgaacgga tccatcttca atgttgtggc gaattttgaa gttagctttg attccattct 
   421 tttgtttgtc tgccgtgatg tatacattgt gtgagttata gttgtactcg agtttgtgtc 
   481 cgagaatgtt tccatcttct ttaaaatcaa taccttttaa ctcgatacga ttaacaaggg 
   541 tatcaccttc aaacttgact tcagcacgcg tcttgtagtt cccgtcatct ttgaaagata 
   601 tagtgcgttc ctgtacataa ccttcgggca tggcactctt gaaaaagtca tgccgtttca 
   661 tatgatccgg ataacgggaa aagcattgaa caccataaga gaaagtagtg acaagtgttg 
   721 gccatggaac aggtagtttt ccagtagtgc aaataaattt aagggtaagt tttccgtatg 
   781 ttgcatcacc ttcaccctct ccactgacag aaaatttgtg cccattaaca tcaccatcta 
   841 attcaacaag aattgggaca actccagtga aaagttcttc tcctttactc atgaattccg 
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   901 cgcaggtcca gcaatgatgt tcaatgcaat acgccacgca cattctagag gggaattgtt 
   961 atccgctcac aattccccta tagtgagtcg tattaatttc gcgggatcga gatctcgatc 
  1021 ctctacgccg gacgcatcgt ggccggcatc accggcgcca caggtgcggt tgctggcgcc 
  1081 tatatcgccg acatcaccga tggggaagat cgggctcgcc acttcgggct catgagcgct 
  1141 tgtttcggcg tgggtatggt ggcaggcccc gtggccgggg gactgttggg cgccatctcc 
  1201 ttgcatgcac cattccttgc ggcggcggtg ctcaacggcc tcaacctact actgggctgc 
  1261 ttcctaatgc aggagtcgca taagggagag cgtcgagatc ccggacacca tcgaatggcg 
  1321 caaaaccttt cgcggtatgg catgatagcg cccggaagag agtcaattca gggtggtgaa 
  1381 tgtgaaacca gtaacgttat acgatgtcgc agagtatgcc ggtgtctctt atcagaccgt 
  1441 ttcccgcgtg gtgaaccagg ccagccacgt ttctgcgaaa acgcgggaaa aagtggaagc 
  1501 ggcgatggcg gagctgaatt acattcccaa ccgcgtggca caacaactgg cgggcaaaca 
  1561 gtcgttgctg attggcgttg ccacctccag tctggccctg cacgcgccgt cgcaaattgt 
  1621 cgcggcgatt aaatctcgcg ccgatcaact gggtgccagc gtggtggtgt cgatggtaga 
  1681 acgaagcggc gtcgaagcct gtaaagcggc ggtgcacaat cttctcgcgc aacgcgtcag 
  1741 tgggctgatc attaactatc cgctggatga ccaggatgcc attgctgtgg aagctgcctg 
  1801 cactaatgtt ccggcgttat ttcttgatgt ctctgaccag acacccatca acagtattat 
  1861 tttctcccat gaagacggta cgcgactggg cgtggagcat ctggtcgcat tgggtcacca 
  1921 gcaaatcgcg ctgttagcgg gcccattaag ttctgtctcg gcgcgtctgc gtctggctgg 
  1981 ctggcataaa tatctcactc gcaatcaaat tcagccgata gcggaacggg aaggcgactg 
  2041 gagtgccatg tccggttttc aacaaaccat gcaaatgctg aatgagggca tcgttcccac 
  2101 tgcgatgctg gttgccaacg atcagatggc gctgggcgca atgcgcgcca ttaccgagtc 
  2161 cgggctgcgc gttggtgcgg atatctcggt agtgggatac gacgataccg aagacagctc 
  2221 atgttatatc ccgccgttaa ccaccatcaa acaggatttt cgcctgctgg ggcaaaccag 
  2281 cgtggaccgc ttgctgcaac tctctcaggg ccaggcggtg aagggcaatc agctgttgcc 
  2341 cgtctcactg gtgaaaagaa aaaccaccct ggcgcccaat acgcaaaccg cctctccccg 
  2401 cgcgttggcc gattcattaa tgcagctggc acgacaggtt tcccgactgg aaagcgggca 
  2461 gtgagcgcaa cgcaattaat gtaagttagc tcactcatta ggcaccggga tctcgaccga 
  2521 tgcccttgag agccttcaac ccagtcagct ccttccggtg ggcgcggggc atgactatcg 
  2581 tcgccgcact tatgactgtc ttctttatca tgcaactcgt aggacaggtg ccggcagcgc 
  2641 tctgggtcat tttcggcgag gaccgctttc gctggagcgc gacgatgatc ggcctgtcgc 
  2701 ttgcggtatt cggaatcttg cacgccctcg ctcaagcctt cgtcactggt cccgccacca 
  2761 aacgtttcgg cgagaagcag gccattatcg ccggcatggc ggccccacgg gtgcgcatga 
  2821 tcgtgctcct gtcgttgagg acccggctag gctggcgggg ttgccttact ggttagcaga 
  2881 atgaatcacc gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg tctgcgacct 
  2941 gagcaacaac atgaatggtc ttcggtttcc gtgtttcgta aagtctggaa acgcggaagt 
  3001 cagcgccctg caccattatg ttccggatct gcatcgcagg atgctgctgg ctaccctgtg 
  3061 gaacacctac atctgtatta acgaagcgct ggcattgacc ctgagtgatt tttctctggt 
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  3121 cccgccgcat ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt 
  3181 catcatcagt aacccgtatc gtgagcatcc tctctcgttt catcggtatc attaccccca 
  3241 tgaacagaaa tcccccttac acggaggcat cagtgaccaa acaggaaaaa accgccctta 
  3301 acatggcccg ctttatcaga agccagacat taacgcttct ggagaaactc aacgagctgg 
  3361 acgcggatga acaggcagac atctgtgaat cgcttcacga ccacgctgat gagctttacc 
  3421 gcagctgcct cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg 
  3481 agacggtcac agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgt 
  3541 cagcgggtgt tggcgggtgt cggggcgcag ccatgaccca gtcacgtagc gatagcggag 
  3601 tgtatactgg cttaactatg cggcatcaga gcagattgta ctgagagtgc accatatatg 
  3661 cggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctcttccgct 
  3721 tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac 
  3781 tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga 
  3841 gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat 
  3901 aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac 
  3961 ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct 
  4021 gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg 
  4081 ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg 
  4141 ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt 
  4201 cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg 
  4261 attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac 
  4321 ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga 
  4381 aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt 
  4441 gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt 
  4501 tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaac 
  4561 aataaaactg tctgcttaca taaacagtaa tacaaggggt gttatgagcc atattcaacg 
  4621 ggaaacgtct tgctctaggc cgcgattaaa ttccaacatg gatgctgatt tatatgggta 
  4681 taaatgggct cgcgataatg tcgggcaatc aggtgcgaca atctatcgat tgtatgggaa 
  4741 gcccgatgcg ccagagttgt ttctgaaaca tggcaaaggt agcgttgcca atgatgttac 
  4801 agatgagatg gtcagactaa actggctgac ggaatttatg cctcttccga ccatcaagca 
  4861 ttttatccgt actcctgatg atgcatggtt actcaccact gcgatccccg ggaaaacagc 
  4921 attccaggta ttagaagaat atcctgattc aggtgaaaat attgttgatg cgctggcagt 
  4981 gttcctgcgc cggttgcatt cgattcctgt ttgtaattgt ccttttaaca gcgatcgcgt 
  5041 atttcgtctc gctcaggcgc aatcacgaat gaataacggt ttggttgatg cgagtgattt 
  5101 tgatgacgag cgtaatggct ggcctgttga acaagtctgg aaagaaatgc ataaactttt 
  5161 gccattctca ccggattcag tcgtcactca tggtgatttc tcacttgata accttatttt 
  5221 tgacgagggg aaattaatag gttgtattga tgttggacga gtcggaatcg cagaccgata 
  5281 ccaggatctt gccatcctat ggaactgcct cggtgagttt tctccttcat tacagaaacg 
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  5341 gctttttcaa aaatatggta ttgataatcc tgatatgaat aaattgcagt ttcatttgat 
  5401 gctcgatgag tttttctaag aattaattca tgagcggata catatttgaa tgtatttaga 
  5461 aaaataaaca aataggggtt ccgcgcacat ttccccgaaa agtgccacct aaattgtaag 
  5521 cgttaatatt ttgttaaaat tcgcgttaaa tttttgttaa atcagctcat tttttaacca 
  5581 ataggccgaa atcggcaaaa tcccttataa atcaaaagaa tagaccgaga tagggttgag 
  5641 tgttgttcca gtttggaaca agagtccact attaaagaac gtggactcca acgtcaaagg 
  5701 gcgaaaaacc gtctatcagg gcgatggccc actacgtgaa ccatcaccct aatcaagttt 
  5761 tttggggtcg aggtgccgta aagcactaaa tcggaaccct aaagggagcc cccgatttag 
  5821 agcttgacgg ggaaagccgg cgaacgtggc gagaaaggaa gggaagaaag cgaaaggagc 
  5881 gggcgctagg gcgctggcaa gtgtagcggt cacgctgcgc gtaaccacca cacccgccgc 
  5941 gcttaatgcg ccgctacagg gcgcgtccca ttcgcca 
// 
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Appendix E. Cloning Reactions  
Table 1. Sample Klenow Extension Reaction. 
 Reaction 1 (P1+TAG) Reaction 2 (P1+GCG) 
Klenow (NEB M0210S 2015) 0.5 µL 0.5 µL 
Oligo 1 (F) 1 µL (1.36 µg)  1 µL (1.36 µg) 
Oligo 2 (R) 1 µL (1.36 µg) 1 µL (1.36 µg) 
10X NEB 2 Buffer (2016) 2.0 µL  2.0 µL 
dNTPs (Promega 12/17) 6.6 µL 6.6 µL 
ddH2O 8.85 µL 8.85 µL 
Total Reaction Volume 20 µL 20 µL 
   
Add EDTA (0.5M stock) 0.4 µL 0.4 µL 
*Incubate reaction for 15 mins at 25℃  
**End reaction by adding 0.4 µL of 0.5M EDTA and heating at 75℃ for 20 minutes  
 
Table 2. Sample Insert Double Digestion Reaction. 
DNA (insert, 1µg) 10 µL 
10X NEB Buffer 5 µL 
Restriction Enzyme 1: EcoRI-HF 1 µL 
Restriction Enzyme 2: XbaI 1 µL 
ddH2O 33 µL 
Total Reaction Volume 50 µL 
*Incubate reaction for 10 hours at 37℃. 
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Table 3. Sample pET28b-GFP Double Digestion Reaction.  
DNA (pET28b-GFP, 1 µg) 10 µL 
Restriction Enzyme 1: EcoRI-HF 1 µL 
Restriction Enzyme 2: XbaI 1 µL 
10X NEB Buffer 5 µL  
ddH2O 33 µL 
Total Reaction Volume 50 µL 
*Incubate reaction for 4 hours at 37℃. 
 
Table 4. Sample Calf Intestinal Alkaline Phosphatase (CIP) Reaction for pET28b-GFP. 
DNA (pET28b-GFP, 1 µg) 15 µL 
10X Cutsmart Buffer 2 µL  
CIP 0.5 µ 
ddH2O 2.5 µL 
Total Reaction Volume 20 µL 
*Incubate reaction for 50 minutes at 37℃.  
 
Table 5. Sample pET28b-GFP + Oligonucleotide Ligation Reaction.  
pET28b-GFP (47.5 ng) 5 µL 
Oligonucleotide (4.82 ng) 3.2 µL 
T4 DNA Ligase 1 µL 
T4 DNA Ligase Buffer 1 µL 
Total Reaction Volume 10.2 µL 
*Incubate reaction for 4 hours at 23℃ 
** Reaction shown is 1:10 pET28b-GFP:oligonucleotide. 1:1 and 1:2 reactions were also 
performed. 
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Appendix F. Project Expenses     
 
Product Cost 
Sequencing $156 
L-arabinose $61 
Oligonucleotides $118.12 
L-DOPA $51.90 
Cloning $535 
Total $922.02 
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Appendix G. Project Timeline 
 
Figure 4. Project Timeline.  
 
